buformin has been researched along with Hyperlipoproteinemia in 2 studies
Buformin: An oral hypoglycemic agent that inhibits gluconeogenesis, increases glycolysis, and decreases glucose oxidation.
buformin : A member of the class of biguanides that is biguanide substituted by a butyl group at position 1. It is an antidiabetic drug with potential antitumor effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pados, G | 1 |
| Schulze, J | 1 |
| Julius, U | 1 |
| Leonhardt, W | 1 |
| Haller, H | 1 |
1 trial available for buformin and Hyperlipoproteinemia
| Article | Year |
|---|---|
[Adverse effect of butylbiguanide therapy on alpha-lipoprotein cholesterol levels].
Topics: Biguanides; Buformin; Cholesterol; Clinical Trials as Topic; Humans; Hyperlipoproteinemias; Lipoprot | 1980 |
1 other study available for buformin and Hyperlipoproteinemia
| Article | Year |
|---|---|
[Metabolism kinetic characterization of hypertriglyceridemias in drug therapy variations].
Topics: Adult; Blood Glucose; Buformin; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Delayed-Action P | 1987 |